Share

August 2015; 2 (4) ArticleOpen Access

Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO

Joanna Kitley, Mark Woodhall, M. Isabel Leite, Jackie Palace, Angela Vincent, Patrick Waters
First published June 18, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000121
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
931

Share

Article Information

vol. 2 no. 4 e121
DOI: 
https://doi.org/10.1212/NXI.0000000000000121
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received January 31, 2015
  • Accepted in final form April 20, 2015
  • First Published June 18, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Joanna Kitley, DPhil,
    2. Mark Woodhall, PhD,
    3. M. Isabel Leite, DPhil,
    4. Jackie Palace, MD,
    5. Angela Vincent, FRS and
    6. Patrick Waters, PhD
  1. Joanna Kitley, DPhil,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Dr Kitley has received speaking honoraria from Novartis and Terumo BCT and support for scientific meetings from Teva, Novartis and Biogen Idec

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Dr Kitley was supported by the NHS National Specialised Commissioning Group for Neuromyelitis Optica from Sep 2010 to Sep 2013.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Mark Woodhall, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. M. Isabel Leite, DPhil,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Dr Leite is supported by NHS National Specialised Commissioning Group for Neuromyelitis optica, UK, and by NIHR Oxford Biomedical Research Centre, and has received speaking honoraria from Biogen Idec and travel and educational grants from Biogen Idec and UK.

    Editorial Boards:

    1. Neuromuscular Disorders, editorial board member, from January 2014

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Jackie Palace, MD,
    5. Scientific Advisory Boards:

    1. UK advisory board participant: 1) Merck Serono 2) Bayer Schering Pharma 3) Biogen Idec 4) Teva Pharmaceutical Industries Ltd. 5) Novartis Pharmaceuticals UK Ltd. 6) Sanofi-Aventis 7) Alexion

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Support for attending ECTRIMS Merck Serono Novartis and Biogen idec Talks at scientific meetings (majority have CME) Bayer schering, Biogen Idec, Merk Serono, Medimmune

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) ISIS innovation Limited, a wholly-owned subsidiary of the University of Oxford, has filed a patent application (WO2013/117930 A2) to protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. In addition to advisory committees, consultant for: Ono Pharmaceuticals Ltd. Chugai Pharma Ltd. CI Consulting Biogen Idec GlaxoSmithKline

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Donations to support local service development and research, none relevant to the current work:Bayer Schering Merke Serono Novartis

    Research Support, Government Entities:

    1. Department of Health Risk Sharing Scheme, Clinical Coordinator since 2002 Department of Health funding for a neuromyelitis optica service and a congenital myasthenia service

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. MS Society UK Guthy Jackson Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Angela Vincent, FRS and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Occasional small honoraria, travel and speaker honoraria from Baxter International Inc and Biogen Inc

    Editorial Boards:

    1. Advisory Editorial Board Neurology; Associate Editor for Brain ended 2013

    Patents:

    1. Hold patent with Oxford University for LGI1/CASPR2 antibodies, licensed to Euroimmun AG, and for GABAAR antibodies, in negotiation with Euroimmun AG.

    Publishing Royalties:

    1. Royalties from Athena Diagnostics (MuSK assays). Royalties received from Euroimmun AG (LGI1 and CASPR2 assays) Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press 2010).

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultancy with Athena Diagnostics for assessing their antibody assays ?5K pa. Ended 2014.

    Speakers' Bureaus:

    1. Scientific conference expenses only

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NIHR general support for antibody work

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Patrick Waters, PhD
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Speaker honoraria from Biogen Idec Japan and Euroimmun AG.

    Editorial Boards:

    1. Frontiers in molecular innate immunity, Review editor

    Patents:

    1. Assays for the detection of antibodies to lgi1, Caspr2, Tag-1 and GABAAR.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Patents for CASPR2, LGI1, TAG-1 and GABAAR.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
  1. Correspondence to Prof. Vincent: angela.vincent{at}ndcn.ox.ac.uk

Article usage

Article usage: June 2015 to October 2023

AbstractFullPdfSource
Jun 201511416725Highwire
Jul 20152253428Highwire
Jul 201508153pmc
Aug 20152993043Highwire
Aug 201502918pmc
Sep 2015581412Highwire
Sep 201504620pmc
Oct 201558139Highwire
Oct 20150139pmc
Nov 201535810Highwire
Nov 201501416pmc
Dec 20154072Highwire
Dec 20150208pmc
Jan 20164559Highwire
Jan 201602413pmc
Feb 20163095Highwire
Feb 2016056pmc
Mar 20164037Highwire
Mar 201601715pmc
Apr 20162835Highwire
Apr 2016083pmc
May 20162641Highwire
May 2016085pmc
Jun 201619103Highwire
Jun 20160102pmc
Jul 20162871Highwire
Jul 2016085pmc
Aug 20162420Highwire
Aug 20160113pmc
Sep 20161302Highwire
Sep 20160154pmc
Oct 20161813Highwire
Oct 20160148pmc
Nov 20161231Highwire
Nov 20160134pmc
Dec 20161663Highwire
Dec 2016069pmc
Jan 20173047Highwire
Jan 20170123pmc
Feb 2017601Highwire
Feb 2017043pmc
Mar 20172533Highwire
Mar 2017073pmc
Apr 20171111Highwire
Apr 2017244pmc
May 2017921Highwire
May 2017154pmc
Jun 20171201Highwire
Jun 201751013pmc
Jul 2017621Highwire
Jul 2017456pmc
Aug 20171121Highwire
Aug 2017188pmc
Sep 2017511Highwire
Sep 2017379pmc
Oct 2017910Highwire
Oct 2017357pmc
Nov 20178142Highwire
Nov 2017266pmc
Dec 2017067Highwire
Jan 20180106Highwire
Feb 2018081Highwire
Mar 20180100Highwire
Apr 20181107Highwire
Apr 2018022pmc
May 20182165Highwire
Jun 20180205Highwire
Jun 2018144pmc
Jul 20180164Highwire
Aug 20181154Highwire
Aug 201821011pmc
Sep 20180121Highwire
Oct 20183111Highwire
Nov 20183174Highwire
Dec 20182143Highwire
Jan 20191123Highwire
Feb 2019592Highwire
Mar 201911112Highwire
Apr 2019179Highwire
May 20194136Highwire
Jun 2019397Highwire
Jul 20199227Highwire
Aug 201971934Highwire
Sep 2019101412Highwire
Oct 2019122210Highwire
Nov 201971813Highwire
Dec 20195204Highwire
Jan 20202281Highwire
Feb 2020093Highwire
Mar 20200135Highwire
Apr 2020275Highwire
May 2020052Highwire
Jun 202022313Highwire
Jul 2020171Highwire
Aug 2020086Highwire
Sep 202021713Highwire
Oct 20200263Highwire
Nov 20201129Highwire
Dec 20203203Highwire
Jan 20211133Highwire
Feb 20210113Highwire
Mar 20211710Highwire
Apr 2021032Highwire
May 2021092Highwire
Jun 20214146Highwire
Jul 202111611Highwire
Aug 20211154Highwire
Sep 20210146Highwire
Oct 202122115Highwire
Nov 202111819Highwire
Dec 20211206Highwire
Jan 202201384Highwire
Feb 20221522Highwire
Mar 20222183Highwire
Apr 20220182Highwire
May 202232311Highwire
Jun 202222510Highwire
Jul 20222192Highwire
Aug 20224222Highwire
Sep 202242915Highwire
Oct 20222776Highwire
Nov 2022726617Highwire
Dec 20222218Highwire
Jan 202343911Highwire
Feb 20232175Highwire
Mar 20230281Highwire
Apr 20233106Highwire
May 20233279Highwire
Jun 20231295Highwire
Jul 20231199Highwire
Aug 20232244Highwire
Sep 20232164Highwire
Oct 20233255Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles